Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in sleeping sickness therapy.

S Van Nieuwenhove1

  • 1ABOS, Belgian Development Cooperation, Brussels.

Annales De La Societe Belge De Medecine Tropicale
|January 1, 1992
PubMed
Summary

Nifurtimox and DFMO are effective treatments for gambiense sleeping sickness, even when resistant to melarsoprol. While toxicity is a concern, these drugs offer new hope for managing this neglected tropical disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unexpected pyomyositis of right buttock.

JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)·2012
Same author

Reversible splenic ischemia in inflammatory bowel disease.

JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)·2011
Same author

Sleeping sickness resurgence in the DRC: the past decade.

Tropical medicine & international health : TM & IH·2001
Same author

Gambiense sleeping sickness: re-emerging and soon untreatable?

Bulletin of the World Health Organization·2001
Same author

Watering sites in Glossina fuscipes habitat as the major foci for the transmission of Gambiense sleeping sickness in an endemic area of southern Sudan.

Annales de la Societe belge de medecine tropicale·1991
Same author

Synergistic activity of 5-substituted 2-nitroimidazoles (Ro 15-0216 and benznidazole) and DL-alpha-difluoromethylornithine on Trypanosoma brucei brucei.

Annales de la Societe belge de medecine tropicale·1990

Area of Science:

  • Medical Research
  • Tropical Medicine
  • Pharmacology

Background:

  • Sleeping sickness, a parasitic disease, requires effective treatment options.
  • Melarsoprol has been a classical treatment but faces challenges with refractory cases and toxicity.
  • Newer agents like nifurtimox and DFMO offer potential alternatives.

Purpose of the Study:

  • To review the efficacy and adverse effects of nifurtimox and DFMO for sleeping sickness.
  • To compare these novel agents with melarsoprol.
  • To discuss optimal use and combination therapies.

Main Methods:

  • Literature review of existing studies on nifurtimox and DFMO.
  • Analysis of efficacy data for gambiense and rhodesiense sleeping sickness.
  • Comparison of adverse effect profiles and toxicity.
  • Discussion of treatment parameters and potential for large-scale use.

Main Results:

  • Nifurtimox and DFMO are effective for gambiense sleeping sickness, including melarsoprol-refractory cases.
  • DFMO shows limited activity against rhodesiense sleeping sickness.
  • Nifurtimox and DFMO have non-negligible toxicity.
  • Melarsoprol, nifurtimox, and DFMO exhibit synergistic activity in experimental models.

Conclusions:

  • Nifurtimox and DFMO represent significant advancements in treating gambiense sleeping sickness.
  • Combination therapy using available drugs like melarsoprol, nifurtimox, and DFMO should be explored for optimized treatment regimens.
  • Further research is needed to fully understand nifurtimox efficacy in rhodesiense sleeping sickness.

Related Experiment Videos